Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

por Arnould, L, Gelly, M, Penault-Llorca, F, Benoit, L, Bonnetain, F, Migeon, C, Cabaret, V, Fermeaux, V, Bertheau, P, Garnier, J, Jeannin, J-F, Coudert, B
Publicado 2006